Angina

Clinical Trial Finder

Many patients with angina are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

GLOBAL LEADERS Adjudication Sub-Study

Conditions:   Coronary Artery Disease;   Platelet-aggregation Inhibitors
Intervention:  
Sponsors:   University Hospital Inselspital, Berne;   European Cardiovascular Research Center
Active, not recruiting - verified August 2017

Hybrid Coronary Revascularization Trial

Condition:   Coronary Artery Disease
Interventions:   Procedure: Hybrid Coronary Revascularization;   Device: Hybrid Coronary Revascularization;   Device: Percutaneous Coronary Intervention
Sponsors:   Emilia Bagiella;   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified August 2017

Efficacy Study of Oral Nicorandil on Improving Microvascular Function in Female Non-obstructive Coronary Artery Disease (CAD) Subjects

Condition:   Non-obstructive Coronary Artery Disease
Interventions:   Drug: Nicorandil;   Drug: Standard treatment
Sponsor:   Merck KGaA
Recruiting - verified August 2017

Influence of Naloxone on Ticagrelor Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris on Concomitant Treatment With Morphine

Condition:   Unstable Angina Pectoris
Interventions:   Drug: Crushed ticagrelor followed by morphine;   Drug: Crushed ticagrelor, morphine,naloxone
Sponsor:   Collegium Medicum w Bydgoszczy
Recruiting - verified August 2017

Influence of Metoclopramide on Ticagrelor Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris on Concomitant Treatment With Morphine

Condition:   Unstable Angina Pectoris
Interventions:   Drug: Crushed ticagrelor followed by morphine;   Drug: Crushed ticagrelor, morphine,metoclopramide
Sponsor:   Collegium Medicum w Bydgoszczy
Recruiting - verified August 2017

In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?

Conditions:   Chest Pain;   Stable Angina;   Acute Coronary Syndrome;   Non ST Segment Elevation Acute Coronary Syndrome
Intervention:   Device: Routine Measurement of FFR
Sponsors:   University Hospital Southampton NHS Foundation Trust;   Liverpool Heart and Chest Hospital NHS Foundation Trust
Recruiting - verified August 2017

Cardiac Rehabilitation Program in Improving Cardiorespiratory Fitness in Stage 0-III Breast Cancer Survivors

Conditions:   Cancer Survivor;   Stage 0 Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions:   Other: Educational Intervention;   Behavioral: Exercise Intervention;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
Sponsor:   Ohio State University Comprehensive Cancer Center
Recruiting - verified August 2017

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified August 2017

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Active, not recruiting - verified August 2017

the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia

Condition:   Coronary Artery Disease
Intervention:   Drug: Febuxostat
Sponsor:   Yokohama City University Medical Center
Terminated - verified August 2017

Compare the Efficacy of Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery

Conditions:   Coronary Artery Bypass;   Antiplatelet Agents
Interventions:   Drug: Aspirin;   Drug: Ticagrelor
Sponsor:   Ruijin Hospital
Completed - verified August 2017

Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)

Condition:   Microvascular Angina
Interventions:   Drug: Ranolazine;   Drug: Placebo
Sponsors:   Emory University;   Gilead Sciences
Recruiting - verified August 2017

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

Condition:   Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Interventions:   Drug: Epanova® (omega-3 carboxylic acids);   Drug: corn oil control
Sponsors:   AstraZeneca;   Cleveland Clinic Coordinating Center for Clinical Research (C5R);   Quintiles, Inc.
Active, not recruiting - verified August 2017

Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control

Conditions:   Atrial Fibrillation;   Atrial Flutter
Interventions:   Drug: Metoprolol;   Drug: Diltiazem
Sponsor:   CAMC Health System
Recruiting - verified August 2017

ABSORB STEMI: the TROFI II Study

Condition:   Acute ST Segment Elevation Myocardial Infarction
Intervention:   Device: Percutaneous Coronary Intervention
Sponsors:   ECRI bv;   Abbott Vascular;   Terumo Europe N.V.
Active, not recruiting - verified August 2017

Coronary Artery Bypass Grafting Strategies for the Anterolateral Territory: a Prospective Randomized Clinical Trial

Condition:   Coronary Artery Disease
Interventions:   Procedure: LIMA to SVG Bridge Technique;   Procedure: Conventional CABG
Sponsors:   Centre hospitalier de l'Université de Montréal (CHUM);   Canadian Institutes of Health Research (CIHR)
Recruiting - verified August 2017

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Condition:   Cardiovascular Disease
Interventions:   Drug: Febuxostat;   Drug: Allopurinol
Sponsors:   Takeda;   Teijin America, Inc.
Completed - verified August 2017

Advantageous Predictors of Acute Coronary Syndromes Evaluation (APACE) Study

Conditions:   Myocardial Infarction;   Angina, Unstable
Intervention:  
Sponsors:   University Hospital, Basel, Switzerland;   Swiss National Science Foundation
Recruiting - verified August 2017